The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: Are we all the way there yet?

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 1, 2006, Pages 61-74

  Nassar, Alaa Eldin F ^a   Talaat, Rasmy E ^b   Kamel, Amin M ^b  

^a Vion Pharmaceuticals Incorporated   (United States)

^b PFIZER INC   (United States)

Author keywords

Drug metabolism; In vitro; In vivo; LC MS; Liquid chromatography mass spectrometry; Metabolic activation; Metabolite characterization; Pharmacokinetic

Indexed keywords

8 QUINOLINOL; ACETYLCYSTEINE; CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE; HYDROCORTISONE; IPRONIAZID; ISONIAZID; LABETALOL; NICOTINIC ACID; PARACETAMOL; POTASSIUM CYANIDE; VALPROIC ACID;

CHIRAL CHROMATOGRAPHY; DERIVATIZATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ION TRAP MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MASS SPECTROMETRY; METABOLIC ACTIVATION; NONHUMAN; ONLINE ANALYSIS; QUALITY CONTROL; RAT; REVIEW; ROBOTICS; SYSTEMATIC REVIEW; TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RADIOACTIVE TRACERS; STEREOISOMERISM;

EID: 30744449005     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Kassel DB: Applications of high-throughput ADME in drug discovery. Curr Opin Chem Biol (2004) 8(3):339-345.
2. Thompson TN: Early ADME in support of drug discovery: The role of metabolic stability studies. Curr Drug Metab (2000) 1(3):215-241.
3. Roberts SA: Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discovery Dev (2003) 6(1):66-80.
4. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM: The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem (2003) 3(10):1125-1154.
5. n and the chemiluminescent nitrogen detector. Anal Chem (2002) 74(13):3232-3238.
6. Lesko LJ, Rowland M, Peck CC, Blaschke TF: Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res (2000) 17(11):11335-1344.
7. Kubinyi H: Quantitative structure-activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J Med Chem (1977) 20(5):625-629.
8. Greene N: Computer systems for the prediction of toxicity: An update. Adv Drug Deliv Rev (2002) 54(3):417-431.
9. Meyboom RH, Lindquist M, Egberts AC: An ABC of drug-related problems. Drug Saf (2000) 22(6):415-423.
10. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc (2002) 287(17):2215-2220.
11. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L: Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther (1995) 58(1):108-117. Provides information on drugs discontinued from 1974 through 1993 in the UK, the US and Spain due to safety issues.
12. Nassar AE, Lopez-Anaya A: Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discovery Dev (2004) 7(1):126-136.
13. Nassar AE, Adam P: Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadrupole time-of-flight mass spectrometry and in silico prediction. Curr Drug Metab (2003) 4(4):259-271.
14. Nassar AE: Online hydrogen-deuterium exchange and a tandem quadrupole time-of-flight mass spectrometer coupled with liquid chromatography for metabolite identification in drug metabolism. J Chromatogr Sci (2003) 41(8):398-404.
15. Nassar AE, Talaat R: Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Disc Today (2004) 9(7):317-327.
16. Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ: Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun Mass Spectrom (2003) 17(23):2632-2638.
17. Kostiainen R, Kotiaho T, Kuuranne T, Auriola S: Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom (2003) 38(4):357-372.
18. Tiller PR, Romanyshyn LA: Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process. Rapid Commun Mass Spectrom (2002) 16(12):1225-1231.
19. Castro-Perez J, Plumb R, Granger JH, Beattie I, Joncour K, Wright A: Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. Rapid Commun Mass Spectrom (2005) 19(6):843-848. Discusses the importance of UPLC.
20. Leclercq L, Delatour C, Hoes I, Brunelle F, Labrique X, Castro-Perez J: Use of a five-channel multiplexed electrospray quadrupole time-of-flight hybrid mass spectrometer for metabolite identification. Rapid Commun Mass Spectrom (2005) 19(12):1611-1618.
21. Yang L, Amad M, Winnik WM, Schoen AE, Schweingruber H, Mylchreest I, Rudewicz PJ: Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays. Rapid Commun Mass Spectrom (2002) 16(21):2060-2066.
22. Johnson KA, Plumb R: Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J Pharm Biomed Anal (2005) 39(3-4):805-810.
23. Jemal M, Ouyang Z, Zhao W, Zhu M, Wu WW: A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability. Rapid Commun Mass Spectrom (2003) 17(24):2732-2740. Provides a strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability.
24. Balimane PV, Pace E, Chong S, Zhu M, Jemal M, Pelt CK: A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. J Pharm Biomed Anal (2005) 39(1-2):8-16.
25. Kapron JT, Jemal M, Duncan G, Kolakowski B, Purves R: Removal of metabolite interference during liquid chromatography/tandem mass spectrometry using high-field asymmetric waveform ion mobility spectrometry. Rapid Commun Mass Spectrom (2005) 19(14):1979-1983.
26. Castro-Perez J, Plumb R, Liang L, Yang E: A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun Mass Spectrom (2005) 19(6):798-804.
27. Jemal M: High-throughput quantitative bioanalysis by LC/MS/MS. Biomed Chromatogr (2000) 14(6):422-429.
28. Jemal M, Bergum J: Effect of the amount of internal standard on the precision of an analytical method. J Clin Pharmacol (1992) 32(7):676-677.
29. Zhang H, Henion J: Comparison between liquid chromatography-time of-flight mass spectrometry and selected reaction monitoring liquid chromatography-mass spectrometry for quantitative determination of idoxifene in human plasma. J Chromatogr B Biomed Sci Appl (2001) 757(1):151-159.
30. Nassar AE, Varshney N, Getek T, Cheng L: Quantitative analysis of hydrocortisone in human urine using a high-performance liquid chromatographic-tandem mass spectrometric-atmospheric-pressure chemical ionization method. J Chromatogr Sci (2001) 39(2):59-64.
31. Nassar AE, Varshney N, Getek T: Quantitative analysis of hydrocortisone in human urine using a high-performance liquid chromatographic-tandem mass spectrometric-atmospheric-pressure chemical ionization method. Anal Lett (2001) 34(12):2047-2062.
32. Jemal M, Ouyang Z: Enhanced resolution triple-quadrupole mass spectrometry for fast quantitative bioanalysis using liquid chromatography/ tandem mass spectrometry: Investigations of parameters that affect ruggedness. Rapid Commun Mass Spectrom (2003) 17(1):24-38.
33. Kapron JT, Jemal M, Duncan G, Kolakowski B, Purves R: Removal of metabolite interference during liquid chromatography/tandem mass spectrometry using high-field asymmetric waveform ion mobility spectrometry. Rapid Commun Mass Spectrom (2005) 19(14):1979-1983.
34. Guevremont R: High-field asymmetric waveform ion mobility spectrometry. A new tool for mass spectrometry. J Chromatogr A (2004) 1058(1-2):3-19.
35. White RE: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Ann Rev Pharmacol Toxicol (2000) 40:133-157.
36. Nassar AE, Kamel AM, Clarimont C: Improving the decision-making process in structural modification of drug candidates: Reducing toxicity. Drug Disc Today (2004) 9(24):1055-1064.
37. Nassar AE, Kamel AM, Clarimont C: Improving the decision-making process in the structural modification of drug candidates: Enhancing metabolic stability. Drug Disc Today (2004) 9(23):1020-1028. Discusses the rule-of-three.
38. Kantharaj E, Tuytelaars A, Proost PE, Ongel Z, Van Assouw HP, Gilissen RA: Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid Commun Mass Spectrom (2003) 17(23):2661-2668.
39. Obach RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos (1999) 27(11):1350-1359.
40. Obach RS: Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos (1997) 25(12):1359-1369.
41. Ariens EJ, Simonis AM: Optimization of pharmacokinetics, an essential aspect of drug development, by 'metabolic stabilization'. In: Strategy in Drug Research: Symposium Proceedings. Elsevier Inc, New York, NY, USA (1982):165-178.
42. Testa B, Meyer JM: Drug metabolism and pharmacokinetics: Implications for drug design. Acta Pharm Jugosl (1990) 40:315-350.
43. Humphrey MJ, Smith DA: Role of metabolism and pharmacokinetic studies in the discovery of new drugs - present and future perspectives. Xenobiotica (1992) 22(7):743-755.
44. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA et al: Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem (2003) 46(21):4572-4585.
45. Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG, Vantuno N et al: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl) carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl] -1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem (2001) 44(21):3343-3346.
46. Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, Baroudy BM: Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem (2002) 45(14):3143-3160.
47. Shou M: Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discovery Dev (2005) 8(1):66-77.
48. McConn DJ, Zhao Z: Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: In vitro study design. Curr Drug Metab (2004) 5(2):141-146.
49. Shou M, Lu W, Kari PH, Xiang C, Liang Y, Lu P, Cui D, Emary WB, Michel KB, Adelsberger JK, Brunner JE, Rodrigues AD: Population pharmacokinetic modeling for enterohepatic recirculation in rhesus monkey. Eur J Pharm Sci (2005) 26(2):151-161.
50. Mortishire-Smith RJ, O'Connor D, Castro-Perez JM, Kirby J: Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis. Rapid Commun Mass Spectrom (2005) 19(18):2659-2670.
51. Wrona M, Mauriala T, Bateman KP, Mortishire-Smith RJ, O'Connor D: 'All-in-one' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom (2005) 19(18):2597-2602.
52. Zhang N, Fountain ST, Bi H, Rossi DT: Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS. Anal Chem (2000) 72(4):800-806.
53. Dear GJ, Plumb RS, Sweatman BC, Ayrton J, Lindon JC, Nicholson JK, Ismail IM: Mass directed peak selection, an efficient method of drug metabolite identification using directly coupled liquid chromatography-mass spectrometry-nuclear magnetic resonance spectroscopy. J Chromatogr B Biomed Sci Appl (2000) 748(1):281-293.
54. Zhang MY, Pace N, Kerns EH, Kleintop T, Kagan N, Sakuma T: Hybrid triple quadrupole-linear ion trap mass spectrometry in fragmentation mechanism studies: Application to structure elucidation of buspirone and one of its metabolites. J Mass Spectrom (2005) 40(8):1017-1029.
55. Marquet P, Saint-Marcoux F, Gamble TN, Leblanc JC: Comparison of a preliminary procedure for the general unknown screening of drugs and toxic compounds using a quadrupole-linear ion-trap mass spectrometer with a liquid chromatography-mass spectrometry reference technique. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 789(1):9-18.
56. Watt AP, Mortishire-Smith RJ, Gerhard U, Thomas SR: Metabolite identification in drug discovery. Curr Opin Drug Discovery Dev (2003) 6(1):57-55.
57. Matzinger P: The danger model: A renewed sense of self. Science (2002) 296(5566):301-305.
58. Pirmohamed M: Adverse drug reactions. Br Med J (1998) 316(7140):1295-1298.
59. Richard AM: Structure-based methods for predicting mutagenicity and carcinogenicity: Are we there yet? Mutat Res (1998) 400(1-2):493-507.
60. Mattocks AR, Legg RF, Jukes R: Trapping of short-lived electrophilic metabolites of pyrrolizidine alkaloids escaping from perfused rat liver. Toxicol Lett (1990) 54(1):93-99.
61. Mehta JR, Ludlum DB: Trapping of DNA-reactive metabolites of therapeutic or carcinogenic agents by carbon-14-labeled synthetic polynucleotides. Cancer Res (1982) 42(8):2996-2999.
62. Chen WG, Zhang C, Avery MJ, Fouda HG: Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv Exp Med Biol (2001) 500:521-524.
63. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA: Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol (2004) 17(1):3-16.
64. Burkhart C, Britschgi M, Strasser I, Depta JP, von Greyerz S, Barnaba V, Pichler WJ: Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin Exp Allergy (2002) 32(11):1635-1643.
65. Soglia JR, Harriman SP, Zhao S, Barberia J, Cole MJ, Boyd JG, Contillo LG: The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J Pharm Biomed Anal (2004) 36(1):105-116.
66. Tang W, Abbott FS: Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry. J Mass Spectrom (1996) 31(8):926-936.
67. Tang W, Abbott FS: A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its α-fluorinated analogue: Phase II metabolism and pharmacokinetics. Drug Metab Dispos (1997) 25(2):219-227.
68. Kassahun K, Abbott F: In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab Dispos (1993) 21(6):1098-1106.
69. Liu L, Wells PG: In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: Potential molecular targets of chemical teratogenesis. Toxicol Appl Pharmacol (1994) 125(2):247-255.
70. Munns AJ, De Voss JJ, Hooper WD, Dickinson RG, Gillam EM: Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol (1997) 10(9):1049-1058.
71. Cuttie L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, Gillam EM: Phenytoin metabolism by human cytochrome P450: Involvement of P460 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos (2000) 28(8):945-950.
72. -*. Free Radic BiOl Med (1999) 27(3-4):329-333.
73. Pritsos CA, Constantinides PP, Tritton TR, Heimbrook DC, Sartorelli AC: Use of high-performance liquid chromatography to detect hydroxyl and superoxide radicals generated from mitomycin C. Anal Biochem (1985) 150(2):294-299.
74. Sanders SP, Bassett DJ, Harrison SJ, Pearse D, Zweier JL, Becker PM: Measurements of free radicals in isolated ischemic lungs and lung mitochondria. Lung (2000) 178(2):105-118.
75. 14C-sodium cyanide during microsomal oxidation. Adv Exp Med Biol (1991) 283:657-664.
76. Zhao Z, Koeplinger KA, Padbury GE, Hauer MJ, Bundy GL, Banitt LS, Schwartz TM, Zimmermann DC, Harbach PR, Mayo JK, Aaron CS: Bioactivation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to reactive intermediates that bind covalently to macromolecules and produce genotoxicity. Chem Res Toxicol (1996) 9(8):1230-1239.
77. Zhao Z, Koeplinger KA, Bundy GL, Banitt LS, Padbury GE, Hauer MJ, Sanders PE: In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1- pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) in the rat. Drug Metab Dispos (1996) 24(2):187-198.
78. Uetrecht JP: Idiosyncratic drug reactions: Possible role of reactive metabolites generated by leukocytes. Pharm Res (1989) 6(4):265-273.
79. Masubuchi Y, Nakayama S, Horie T: Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology (2002) 35(3):544-551.
80. Masubuchi Y, Yamada S, Horie T: Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther (2000) 292(3):982-987.
81. 2+-dependent inner-membrane permeability transition. Biochem J (1993) 294(Pt 3):719-725.
82. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, Ookawara T, Suzuki K, Honke K, Taniguchi N: Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem (2003) 384(4):567-574.
83. Nikulina MA, Andersen HU, Karlsen AE, Darville MI, Eizirik DL, Mandrup-Poulsen T: Glutathione depletion inhibits IL-1β-stimulated nitric oxide production by reducing inducible nitric oxide synthase gene expression. Cytokine (2000) 12(9):1391-1394.
84. Yin JH, Yang DI, Chou H, Thompson EM, Xu J, Hsu CY: Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1- nitrosourea in C6 glioma cells. J Pharmacol Exp Ther (2001) 297(1):308-315.
85. O'Donovan DJ, Fernandes CJ: Mitochondrial glutathione and oxidative stress: Implications for pulmonary oxygen toxicity in premature infants. Mol Genet Metab (2000) 71(1-2):352-358.
86. Ilyin SE, Belkowski SM, Plata-Salaman CR: Biomarker discovery and validation: Technologies and integrative approaches. Trends Biotechnol (2004) 22(8):411-416.
87. Lesko LJ, Atkinson AJ Jr: Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol (2001) 41:347-366.
88. Colburn WA: Biomarkers in drug discovery and development: From target identification through drug marketing. J Clin Pharmacol (2003) 43(4):329-341.
89. Nassar AE, de Maio W, Davis M, Talaat RE: Detecting and minimizing reactive intermediates in R&D. Curr Drug Disc (2004):20-25.
90. Madden S, Woolf TF, Pool WF, Park BK: An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol (2004) 46(1):13-20.
91. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA: Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol (2001) 14(1):62-70.
92. Tettey JN, Maggs JL, Rapeport WG, Pirmohamed M, Park BK: Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem Res Toxicol (2001) 14(8):965-974.
93. Gilbert JD, Olah TV, Morris MJ, Bortnick A, Brunner J: The use of stable isotope labeling and liquid chromatography-tandem mass spectrometry techniques to simultaneously determine the oral and ophthalmic bioavailability of timolol in dogs. J Chromatogr Sci (1998) 36(4):163-168.
94. n and the chemiluminescent nitrogen detector. Anal Chem (2002) 74(13):3232-3238.
95. Baillie TA, Rettenmeier AW: Drug biotransformation: Mechanistic studies with stable isotopes. J Clin Pharmacol (1986) 26(6):448-451.
96. Barrish A, Olah TV, Gatto GJ, Michel KB, Dobrinska MR, Gilbert JD: The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 (rizatriptan) in dogs. Rapid Commun Mass Spectrom (1996) 10(9):1033-1037.
97. Chavez-Eng CM, Constanzer ML, Matuszewski BK: High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 767(1):117-129.
98. Boemsen OK, Floeckher JM, Bruin GJM: Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism. Anal Chem (2000) 72(16):3956-3959.
99. Nassar AE, Bjorge SM, Lee DY: On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem (2003) 75(4):785-790.
100. Nassar AE, Parmentier Y, Martinet M, Lee DY: Liquid chromatography- accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies. J Chromatogr Sci (2004) 42(7):348-353.
101. Desai MJ, Armstrong DW: Analysis of derivatized and underivatized theanine enantiomers by high-performance liquid chromatography/atmospheric pressure ionization-mass spectrometry. Rapid Commun Mass Spectrom (2004) 18(3):251-256.
102. Berthod A, Jin HL, Beesley TE, Duncan JD, Armstrong DW: Cyclodextrin chiral stationary phases for liquid chromatographic separations of drug stereoisomers. J Pharm Biomed Anal (1990) 8(2):123-130.
103. Nassar AE, Guarco FJ, Gran DE, Sturat JD, Reuter WM: Optimizing a method for separating chiral compounds by capillary electrophoresis. J Chrom Science (1998) 36:19-22.
104. Berthod A, Jin HL, Beesley TE, Duncan JD, Armstrong DW: Cyclodextrin chiral stationary phases for liquid chromatographic separations of drug stereoisomers. J Pharm Biomed Anal (1990) 8(2):123-130.
105. Wu ST, Xing J, Apedo A, Wang-Iverson DB, Olah TV, Tymiak AA, Zhao N: High-throughput chiral analysis of albuterol enantiomers in dog plasma using on-line sample extraction/polar organic mode chiral liquid chromatography with tandem mass spectrometric detection. Rapid Commun Mass Spectrom (2004) 18(21):2531-2536.